Affinity Asset Advisors »

Galectin Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $3.3M 1.2M 2.75

More positions owned by Affinity Asset Advisors

Xenon Pharmaceuticals (XENE)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Cassava Sciences Put Option (SAVA)
Apogee Therapeutics (APGE)
Nuvalent Inc-a (NUVL)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Nurix Therapeutics (NRIX)
Vera Therapeutics Cl A (VERA)
Verona Pharma Sponsored Ads (VRNA)
Autolus Therapeutics Spon Ads (AUTL)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Inozyme Pharma (INZY)

View all positions for Affinity Asset Advisors

Top funds holding Galectin Therapeutics

Vanguard Group
BlackRock
BlackRock
Affinity Asset Advisors
Advisor Group Holdings
Ikarian Capital
Geode Capital Management
Commonwealth Equity Services
Sontag Advisory
Geneos Wealth Management
Susquehanna International
Northern Trust
State Street Corporation
Morgan Stanley
Atria Wealth Solutions

View all funds holding Galectin Therapeutics